Editorial Policy
How we source, write, and stand behind our content.
Last updated: August 2026
Peptide Research News covers one of the fastest-moving and noisiest topics in health. These are the standards we hold ourselves to so you can trust what you read here.
Educational, not medical advice
Everything we publish is for education and information. It is not medical advice, not a diagnosis, and not a recommendation to use any substance. Many peptides are not approved for human use and are sold for research purposes only. Decisions about your health belong to you and a qualified, licensed clinician.
How we source
- Research is pulled from peer-reviewed literature indexed in PubMed (NCBI).
- News aggregates headlines from established outlets and links back to the original source — we don't republish others' reporting as our own.
- Video is drawn only from a vetted allow-list of clinicians and educators, not open search.
- Reference guides are written to describe what is and isn't established, hedge appropriately, and clearly state regulatory status. We deliberately avoid dosing guidance.
Source hierarchy
PRN weighs sources in roughly this order: regulators and official labels, peer-reviewed systematic reviews, randomized human trials, other human studies, preclinical research, qualified expert commentary, then news reporting. Supplier marketing is never treated as scientific evidence.
Evidence labels
Our guide pages use plain-language evidence classifications to help readers separate approved prescription medicines from investigational compounds and mostly preclinical research peptides. These classifications are editorial aids, not clinical recommendations.
Automation and human review
Automation helps PRN monitor PubMed, news, video and podcast sources. Automated feeds are discovery tools. The high-value pages — guides, supplier standards, testing explainers and Canada resources — are organized and edited by the PRN editorial team.
Accuracy and hedging
Where evidence is preliminary, preclinical, or anecdotal, we say so. Where a claim is backed by robust human trials, we say that too. We would rather tell you “the evidence is limited” than overstate a benefit. Pricing and availability in fast-moving categories (like GLP-1 telehealth) are labeled as reported starting points to be verified, not guarantees.
Independence
Some links on this site are affiliate links (see our Affiliate Disclosure). Commercial relationships never determine whether something is included, how it's ranked, or how it's described. Editorial and commercial are kept separate on purpose.
Corrections
We're not infallible. If you spot something inaccurate or out of date, please tell us and we'll review and correct it. Getting it right matters more to us than being right the first time.